CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. / Xiaomin Zhang; Lingling Zhu; Hui Zhang [and others].

By: Contributor(s): Material type: ArticleLanguage: English Publisher: [Place of publication not identified] : Frontiers Media SA, 2022Description: 1 online resource (1 article)Content type:
  • text
Media type:
  • computer
Carrier type:
  • online resource
Subject(s): Genre/Form: In: Frontiers in immunology Vol. 13, (2022), pages/article 927153Abstract: Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies. At present, CD19 and BCMA are the most common targets in CAR-T cell therapy, and numerous novel therapeutic targets are being explored. However, the adverse events related to CAR-T cell therapy might be serious or even life-threatening, such as cytokine release syndrome (CRS), CAR-T-cell-related encephalopathy syndrome (CRES), infections, cytopenia, and CRS-related coagulopathy. In addition, due to antigen escape, the limited CAR-T cell persistence, and immunosuppressive tumor microenvironment, a considerable proportion of patients relapse after CAR-T cell therapy. Thus, in this review, we focus on the progress and challenges of CAR-T cell therapy in hematological malignancies, such as attractive therapeutic targets, CAR-T related toxicities, and resistance to CAR-T cell therapy, and provide some practical recommendations.
List(s) this item appears in: Open Access Resources
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
No physical items for this record

Publication type: Review article.

Linked open-access copy: published version.

Open access; no subscription required for the linked open-access version. Unrestricted online access star

Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies. At present, CD19 and BCMA are the most common targets in CAR-T cell therapy, and numerous novel therapeutic targets are being explored. However, the adverse events related to CAR-T cell therapy might be serious or even life-threatening, such as cytokine release syndrome (CRS), CAR-T-cell-related encephalopathy syndrome (CRES), infections, cytopenia, and CRS-related coagulopathy. In addition, due to antigen escape, the limited CAR-T cell persistence, and immunosuppressive tumor microenvironment, a considerable proportion of patients relapse after CAR-T cell therapy. Thus, in this review, we focus on the progress and challenges of CAR-T cell therapy in hematological malignancies, such as attractive therapeutic targets, CAR-T related toxicities, and resistance to CAR-T cell therapy, and provide some practical recommendations.

Creative Commons Attribution (licence family recorded by the source; version not supplied in metadata).

https://europepmc.org/articles/PMC9226391

In English.

Description generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.

Course allocation: B. Sc. Medical Laboratory Science.

There are no comments on this title.

to post a comment.